|
Scancell Holdings PLC - Nottingham, England-based cancer immunotherapies developer - In the year that ended April 30, pretax loss narrows to £3.8 million from £16.8 million a year before. Records no revenue in either year. Spends more on development and administration, which is offset by a gain of £7.2 million on substantial modification of convertible loan notes, compared to no such gain in the previous year. Expects early safety and efficacy data from the ModiFY study in the coming year.
"It has been a year of strong operational and clinical progress for Scancell with three vaccine candidates now in the clinic and the antibody platforms gathering momentum with expanded internal research and external validation," says Chief Executive Officer Lindy Durrant.
On Thursday, the firm announced that John Chiplin will step down as executive chair once a replacement is found, and Co-Founder Richard Goodfellow will retire as non-executive director at its annual general meeting.
Current stock price: 15.77 pence, up 4.1% on Friday in London
12-month change: down 21%
Copyright 2022 Alliance News Limited. All Rights Reserved.
|
